In an extraordinary general meeting held on April 3, 2024, in Stockholm, Sweden, PMD Device Solutions AB (publ) made several important resolutions. One of the main resolutions passed was the election of HLB Auditoriet AB as the new auditing firm. Martin Gustafsson was also elected as the new auditor, with Mats-Åke Andersson serving as the deputy auditor until the next Annual General Meeting.
Another significant decision made during the meeting was regarding the remuneration to the auditor. It was resolved that the remuneration will be paid according to approved invoices.
PMDS, an abbreviation for PMD Device Solutions, is a leading company in the development and sale of medical products for respiratory monitoring. Their primary product is called RespiraSense™, which is used for monitoring respiratory rate. Its purpose is to detect deterioration of a patient’s general condition at an early stage, thus preventing respiratory failure and adverse patient outcomes. PMDS takes pride in the fact that RespiraSense™ is the only continuous, motion-tolerant respiratory rate monitor available in the market that delivers class-leading reliability in measuring respiratory rate. In 2022, PMDS received FDA approval for RespiraSense™, further solidifying its status in the industry. Currently, RespiraSense™ is being used in 25 hospitals across the United Kingdom and Ireland. PMDS’s goal is to increase its market share not only in the United Kingdom but also in Germany and the United States.
For those who seek additional information, Myles Murray, the CEO of PMD Device Solutions, can be contacted. He can be reached at +353 86 887 4994 or via email at [email protected] Inquiries related to general matters can be directed to [email protected] The Certified Adviser for the company is Redeye.
It is worth mentioning again that PMDS develops and sells medical products for respiratory monitoring in both hospital and homecare settings. RespiraSense, their primary product, aims to support the early detection of patient deterioration and preventable respiratory failure, thus improving patient outcomes. The unique feature of RespiraSense lies in its ability to continuously monitor respiratory rate even during motion, making it a highly reliable device. The technology has already received commercialization in Europe and the UK, and it has also obtained FDA clearance for use in the United States. PMD Device Solutions AB shares are listed on Nasdaq First North Growth Market with the ticker symbol PMDS.
To find more details, those interested can refer to the Bulletin from the Extraordinary General Meeting of PMD Device Solutions AB held on April 3, 2024. The source of this information is PMD Device Solutions.
